Blog

Vivek Subbiah: An enlightening panel discussion on the latest advancements in oncology at SCRI meeting

Vivek Subbiah/LinkedIn

Nov 15, 2024, 16:13

Vivek Subbiah: An enlightening panel discussion on the latest advancements in oncology at SCRI meeting

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:

“Absolutely thrilled to have been part of an enlightening panel discussion with esteemed colleagues Drs. Navneet Majhail, Melissa Johnson, Dax Kurbegov, Richard Geer and Andy Kennedy on the latest advancements in oncology at Sarah Cannon Research Institute meeting.

Here are some key takeaways:

Targeted Therapy Innovations eg. KRAS inhibitors
CAR-T Cell Therapy
CAR-NK therapies
Novel Immune Checkpoint Inhibitors
Tumor Agnostic Therapies
Antibody-Drug Conjugates (ADCs), Bi-specifics and Radioligands
Next-Generation Sequencing (NGS) and Liquid Biopsies
AI in Oncology
Robotic surgeries/Outpatient surgeries
and much much more

Excited for what’s ahead!”

Vivek Subbiah: An enlightening panel discussion on the latest advancements in oncology at SCRI meeting

More posts featuring Vivek Subbiah.

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.

He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.